Plasma level of dabigatran comparison between geriatric and young patients with atrial fibrillation dabigatran, geriatric, atrial fibrillation, plasma level, therapeutic drug monitoring
Conditions
Interventions
Patients who are more than or equal sixty-five years old and receive dabigatran.,Patients who are less than sixty-five years old and receive dabigatran.
Experimental Drug,Experimental Drug
Sponsors
Faculty of Pharmacy, Silpakorn University
Eligibility
Sex/Gender
All
Age
20 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Thai patient who was more than twenty years old and got dabigatran 150 milligrams or 110 milligrams twice daily for non-valvular atrial fibrillation indication. 2. Good compliance 100 percents and no change dabigatran at least 7 days. 3. The patient signed informed consent; if they can't decide, care given can sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patient with mechanical valve replacement or moderate to severe mitral stenosis. 2. ESRD patient or creatinine clearance less than 30 ml/min. 3. Pregnancy or lactation patient. 4. Active bleeding 5. Platelet count less than 100,000 cell/mm3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dabigatran trough level 10-16 hours after the patient receives dabigatran Chromogenic assay,Dabigatran peak level 2-4 hours after the patient receives dabigatran Chromogenic assay | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactAthitiya Subsorn
Faculty of Pharmacy, Silpakorn University
Outcome results
None listed